M.D. Anderson Cancer Center: Prostatic Neoplasms trials

The registry lists 116 Prostatic Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 20 are open to participants now and 25 have results posted.

Early Phase 1 3Phase 1 19Phase 2 55Phase 3 8Phase 4 1No phase 38(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment PlansNot yet recruitingNCT07852949Not applicable
• Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson HospitalRecruitingNCT07591701Not applicable
• Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate CancerRecruitingNCT07377006Not applicable
• iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate CancerNot yet recruitingNCT07105020Not applicable
• Mediterranean Diet Intervention Among Men at LBJ Hospital With Prostate CancerEnrolling by invitationNCT06935097Not applicable
• A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCRecruitingNCT06826768Phase 1
• Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy TestingRecruitingNCT06785441
• Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyRecruitingNCT06759701Early Phase 1
• PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.RecruitingNCT06274047Phase 3
• Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)RecruitingNCT06085729Phase 1/2
• A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical ProstatectomyRecruitingNCT06085664Phase 1/2
• NeoAdjuvant Theranostic Lutetium Study: The Nautilus TrialRecruitingNCT06066437Phase 1/2
• Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingNCT05873192Phase 2
• Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active SurveillanceRecruitingNCT05840484
• Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability TestingRecruitingNCT05497024
• An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate CancerRecruitingNCT05454488Phase 2
• Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit MonitoringRecruitingNCT05054296Phase 2
• Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)RecruitingNCT05043012Not applicable
• Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingNCT04947254Phase 2
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruitingNCT04693377Not applicable
• An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate CancerTerminatedNCT04134208Phase 4Results posted
• Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE StudyTerminatedNCT04066894Phase 2Results posted
• Apalutamide in Treating Patients With Prostate Cancer Before Radical ProstatectomyActive, not recruitingNCT03412396Phase 2Results posted
• Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate CancerCompletedNCT03279250Phase 2Results posted
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesActive, not recruitingNCT03217747Phase 1/2Results posted
• Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03204812Phase 2Results posted
• Radium 223 in Castrate Resistant Prostate Cancer Bone MetastasesCompletedNCT02135484Not applicableResults posted
• Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)TerminatedNCT01994590Phase 2Results posted
• Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and EnzalutamideCompletedNCT01946165Phase 2Results posted
• Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerCompletedNCT01630590Phase 2Results posted
• A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicableResults posted
• Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate CancerCompletedNCT01505868Phase 1/2Results posted
• Ipilimumab + Androgen Depravation Therapy in Prostate CancerTerminatedNCT01377389Phase 2Results posted
• Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesCompletedNCT01254864Phase 2Results posted
• Neoadjuvant Ipilimumab in Prostate CancerCompletedNCT01194271Phase 2Results posted
• Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate CancerCompletedNCT01076335Phase 2Results posted
• TKI258 in Castrate Resistant Prostate CancerCompletedNCT00831792Phase 2Results posted
• A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using HypofractionationStatus unknownNCT00667888Phase 3Results posted
• Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate CancerCompletedNCT00514540Phase 2Results posted
• Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate CancerCompletedNCT00500110Phase 2Results posted
• External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate CancerTerminatedNCT00388804Phase 3Results posted
• A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle ContrastTerminatedNCT00147238Not applicableResults posted
• Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone MetastasesCompletedNCT00081159Phase 2Results posted
• Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate CancerTerminatedNCT00024167Phase 3Results posted
• Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for RecurrenceTerminatedNCT00003645Phase 3Results posted
• Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate CancerActive, not recruitingNCT05055843Not applicable
• An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate CancerActive, not recruitingNCT05047965Early Phase 1
• Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With HistopathologyWithdrawnNCT05046782Phase 2
• A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)WithdrawnNCT05035732Not applicable
• Gallium-68 PSMA-11 PET in Participants With Prostate CancerWithdrawnNCT05034562Phase 2
• Neoadjuvant Dietary Intervention in Intermediate Risk Prostate CancerActive, not recruitingNCT04985565Not applicable
• An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate CancerCompletedNCT04978675Phase 1
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerTerminatedNCT04754425Phase 2
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04592237Phase 2
• Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART StudyWithdrawnNCT04585932Phase 2
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
• Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African AmericansActive, not recruitingNCT04215029Not applicable
• Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their PartnersActive, not recruitingNCT04189770
• Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate CancerCompletedNCT04106245Not applicable
• Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate CancerActive, not recruitingNCT03987386Phase 3
• Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerActive, not recruitingNCT03821792Phase 2
• A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsCompletedNCT03784677Phase 1
• Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate CancerActive, not recruitingNCT03772834Phase 2/3
• Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate CancerWithdrawnNCT03581500Phase 2
• Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their PartnersActive, not recruitingNCT03575832Not applicable
• Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate CancerTerminatedNCT03360721Phase 2
• Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCCompletedNCT03263650Phase 2
• Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate CancerCompletedNCT03177460Phase 1
• Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate CancerActive, not recruitingNCT03085043Not applicable
• Neoadjuvant Listeria or Daratumumab in Prostate CancerWithdrawnNCT03035357Phase 2
• Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02703623Phase 2
• Randomized AmnioFix Study During Radical ProstatectomyWithdrawnNCT02645591Phase 2
• AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)WithdrawnNCT02420587Phase 2
• T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate CancerCompletedNCT02113657Early Phase 1
• Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerActive, not recruitingNCT01786265Phase 2
• Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)CompletedNCT01751438Phase 2
• Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking MenCompletedNCT01447186
• Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation TherapyActive, not recruitingNCT01410942Phase 2
• A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and ObesityTerminatedNCT01262664Phase 1
• Lenalidomide and Paclitaxel in Prostate CancerTerminatedNCT00933426Phase 1
• Urodynamic Evaluation in Post-radiation Salvage Prostatectomy PatientsTerminatedNCT00901420
• Prostate Conformal CryotherapyCompletedNCT00877682Not applicable
• Quality of Life in Men With High Risk Localized Prostate CancerWithdrawnNCT00877617
• BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone MetsCompletedNCT00872157Phase 1
• Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomyStatus unknownNCT00850941
• Questionnaire and Fall Risk AssessmentCompletedNCT00836238
• Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical ProstatectomyTerminatedNCT00824902Not applicable
• Topical Cyclosporine vs. Placebo for Epiphora Associated With DocetaxelWithdrawnNCT00824811Phase 2
• Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)WithdrawnNCT00811031Phase 2
• Efficacy of Cancer Support Programs: A Social Comparison Theory AnalysisTerminatedNCT00798187
• Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate CancerCompletedNCT00631527Phase 1
• Testosterone in Castration-Resistant Prostate CancerWithdrawnNCT00577980Phase 2
• Quality of Life Study for Prostate Cancer PatientsStatus unknownNCT00561444
• Brachytherapy for Prostatic Carcinoma PatientsActive, not recruitingNCT00525720Phase 2
• CHESS: Human and Computer Mentors for Prostate Cancer PatientsCompletedNCT00516256Not applicable
• Ambulatory Cancer Pain Management: A Feasibility StudyCompletedNCT00507351
• Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation TherapyCompletedNCT00499421
• Active Surveillance in Prostate CancerCompletedNCT00490763
• Study of Quality of Life for Prostate Proton TherapyStatus unknownNCT00489814
• 3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of ProstateTerminatedNCT00464724Not applicable